Cargando…

Comparison of Glycemic Control between Continuous Regular Insulin Infusion and Single-dose Subcutaneous Insulin Glargine Injection in Medical Critically Ill Patients

BACKGROUND AND AIMS: This study aimed to compare glycemic control between continuous intravenous regular insulin infusion and single-dose subcutaneous insulin glargine injection in medical critically ill patients. SUBJECTS AND METHODS: A prospective noninferiority study was conducted in medical crit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhurayanontachai, Rungsun, Rattanaprapat, Tharittamon, Kongkamol, Chanon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879860/ https://www.ncbi.nlm.nih.gov/pubmed/29657375 http://dx.doi.org/10.4103/ijccm.IJCCM_273_17

Ejemplares similares

Glargine insulin: an alternative to regular insulin for glycemic control in critically ill patients
por: Bhattacharyya, M, et al.
Publicado: (2007)

Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes
por: GAO, GUAN-QI, et al.
Publicado: (2014)

Faster Insulin Aspart for Continuous Subcutaneous Insulin Infusion: Is It Worth It?
por: Rosinha, Patrícia, et al.
Publicado: (2022)

Continuous subcutaneous insulin infusion: practical issues
por: Saboo, Banshi D., et al.
Publicado: (2012)

Human regular U‐500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study
por: Grunberger, George, et al.
Publicado: (2020)

Changes in Glycemic Control and Quality of Life in Pediatric Type 1 Diabetics with Continuous Subcutaneous Insulin Infusion of Insulin Aspart Following Multiple Daily Injection Therapy
por: Kawamura, Tomoyuki, et al.
Publicado: (2008)

A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes
por: Lin, Shuo, et al.
Publicado: (2018)

Continuous Subcutaneous Insulin Infusion Therapy Resulting in Improved Glycemic Control in Patient With Low Health Literacy
por: Mandal, Shobha, et al.
Publicado: (2021)

Continuous subcutaneous insulin infusion therapy is associated with reduced retinopathy progression compared with multiple daily injections of insulin
por: Reid, Laura J., et al.
Publicado: (2021)

A Continuous Subcutaneous Insulin Infusion Needle Break
por: George, Minu M., et al.
Publicado: (2015)

Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
por: Bode, Bruce W., et al.
Publicado: (2017)

Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients
por: Lv, Wen-shan, et al.
Publicado: (2013)

Patient‐reported outcomes in a study of human regular U‐500 insulin delivered by continuous subcutaneous insulin infusion or multiple daily injections in patients with type 2 diabetes
por: Chen, Jieling, et al.
Publicado: (2020)

Glargine versus regular insulin protocol in feline diabetic ketoacidosis
por: Zeugswetter, Florian K., et al.
Publicado: (2021)

Management of glycemic variation in diabetic patients receiving parenteral nutrition by continuous subcutaneous insulin infusion (CSII) therapy
por: Li, Feng-fei, et al.
Publicado: (2018)

Psychopathology and Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes
por: Rotella, Francesco, et al.
Publicado: (2013)

Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 Diabetes
por: Lucidi, Paola, et al.
Publicado: (2012)

Maximal Glycemic Difference, the Possible Strongest Glycemic Variability Parameter to Predict Mortality in ICU Patients
por: Issarawattana, Thanaphruet, et al.
Publicado: (2020)

Risk Factors for Glycemic Control in Hospitalized Patients with Type 2 Diabetes Receiving Continuous Subcutaneous Insulin Infusion Therapy
por: Wang, Shun-hua, et al.
Publicado: (2022)

Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes: A randomized open parallel multicenter study
por: Bolli, Geremia B., et al.
Publicado: (2009)

Evaluation of the Accuracy of Current Tubeless Pumps for Continuous Subcutaneous Insulin Infusion
por: Ziegler, Ralph, et al.
Publicado: (2021)

Hypersensitivity reaction associated with subcutaneous glargine insulin therapy in a cat
por: Murphy, Lisa A, et al.
Publicado: (2016)

Continuous subcutaneous insulin infusion is associated with a better glycemic control than multiple daily insulin injections without difference in diabetic ketoacidosis and hypoglycemia admissions among Emiratis with Type 1 diabetes
por: Almazrouei, Raya, et al.
Publicado: (2022)

Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes
por: Li, Feng-fei, et al.
Publicado: (2018)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Associations between bolus infusion of hydrocortisone, glycemic variability and insulin infusion rate variability in critically Ill patients under moderate glycemic control
por: van Hooijdonk, Roosmarijn T. M., et al.
Publicado: (2015)

The relationship between the frequency of self-monitoring of blood glucose and glycemic control in patients with type 1 diabetes mellitus on continuous subcutaneous insulin infusion or on multiple daily injections
por: Murata, Takashi, et al.
Publicado: (2015)

Nocturnal Glycemic Control with New Insulin Glargine 300 U/mL
por: Yu, Neng Chun
Publicado: (2019)

Continuous subcutaneous insulin infusion is associated with a reduced rate of microvascular complications
por: Zabeen, Bedowra, et al.
Publicado: (2015)

Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics
por: Pozzilli, Paolo, et al.
Publicado: (2015)

Continuous subcutaneous insulin infusion and flash glucose monitoring in diabetic hemiballism-hemichorea
por: Qiang, Wei, et al.
Publicado: (2020)

Effect of carbohydrate counting using bolus calculators on glycemic control in type 1 diabetes patients during continuous subcutaneous insulin infusion
por: Yamada, Eijiro, et al.
Publicado: (2017)

Disordered eating behaviour in adolescents with type 1 diabetes on continuous subcutaneous insulin infusion; relation to body image, depression and glycemic control
por: Salah, Nouran Yousef, et al.
Publicado: (2022)

The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care
por: Hilgenfeld, Rolf, et al.
Publicado: (2014)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Insulin Pump for Type 2 Diabetes: Use and misuse of continuous subcutaneous insulin infusion in type 2 diabetes
por: Reznik, Yves, et al.
Publicado: (2013)

Detailed Analysis of Insulin Absorption Variability and the Tissue Response to Continuous Subcutaneous Insulin Infusion Catheter Implantation in Swine
por: Hauzenberger, Jasmin R., et al.
Publicado: (2017)

A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes
por: King, Allen B., et al.
Publicado: (2016)

Effectiveness of Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion for Children with Type 1 Diabetes Mellitus in Clinical Practice
por: Gong, Chun-xiu, et al.
Publicado: (2014)

Study protocol for a randomised controlled trial of insulin delivery by continuous subcutaneous infusion compared to multiple daily injections
por: Blair, Jo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6196pm8cb2bokq23rh6osol2qg